Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains les...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1611375/full |
| _version_ | 1827293186941255680 |
|---|---|
| author | Andrea Ceglédi Zoltán Csukly Mónika Fekete András Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics Gábor Mikala |
| author_facet | Andrea Ceglédi Zoltán Csukly Mónika Fekete András Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics Gábor Mikala |
| author_sort | Andrea Ceglédi |
| collection | DOAJ |
| description | Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains less investigated.Methods: In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes.Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and alkylator treatment refractory patient, achieved sustained stringent complete remission (sCR) after combining carfilzomib-dexamethasone with venetoclax, which was his best response ever. Similarly, Patient 2, refractory to frontline bortezomib-thalidomide-dexamethasone therapy, attained CR following a transition to bortezomib-dexamethason-venetoclax treatment. Patient 3, who was immunomodulatory (IMID)-intolerant, showed a highly favorable response to venetoclax-dexamethasone therapy after his first relapse following autologous stem cell transplantation. No significant adverse effects were observed in any of the patients.Discussion: Our study provides compelling preliminary evidence for the efficacy of venetoclax in t(6;14) translocation-associated myeloma. The outcomes observed in our patients suggest that venetoclax-based therapy holds substantial promise as an effective treatment option for this specific genetic subgroup. Furthermore, the similarities in treatment response between t(11;14) and t(6;14) translocation subgroups highlight the importance of personalized approaches targeting specific genetic abnormalities to optimize therapeutic outcomes. |
| first_indexed | 2024-04-24T13:19:55Z |
| format | Article |
| id | doaj.art-f1942aab14334e64bc29fb8dba190576 |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T13:19:55Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-f1942aab14334e64bc29fb8dba1905762024-04-04T16:20:44ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072023-11-012910.3389/pore.2023.16113751611375Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)Andrea Ceglédi0Zoltán Csukly1Mónika Fekete2András Kozma3Zsuzsanna Szemlaky4Hajnalka Andrikovics5Gábor Mikala6Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, HungaryDepartment of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, HungaryDepartment of Public Health, Semmelweis University, Budapest, HungaryLaboratory of Molecular Genetics, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, HungaryDepartment of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, HungaryLaboratory of Molecular Genetics, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, HungaryDepartment of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, HungaryIntroduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains less investigated.Methods: In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes.Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and alkylator treatment refractory patient, achieved sustained stringent complete remission (sCR) after combining carfilzomib-dexamethasone with venetoclax, which was his best response ever. Similarly, Patient 2, refractory to frontline bortezomib-thalidomide-dexamethasone therapy, attained CR following a transition to bortezomib-dexamethason-venetoclax treatment. Patient 3, who was immunomodulatory (IMID)-intolerant, showed a highly favorable response to venetoclax-dexamethasone therapy after his first relapse following autologous stem cell transplantation. No significant adverse effects were observed in any of the patients.Discussion: Our study provides compelling preliminary evidence for the efficacy of venetoclax in t(6;14) translocation-associated myeloma. The outcomes observed in our patients suggest that venetoclax-based therapy holds substantial promise as an effective treatment option for this specific genetic subgroup. Furthermore, the similarities in treatment response between t(11;14) and t(6;14) translocation subgroups highlight the importance of personalized approaches targeting specific genetic abnormalities to optimize therapeutic outcomes.https://www.por-journal.com/articles/10.3389/pore.2023.1611375/fullmultiple myelomavenetoclaxtranslocation t(6;14)IGH::CCND3personalized therapy |
| spellingShingle | Andrea Ceglédi Zoltán Csukly Mónika Fekete András Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics Gábor Mikala Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) Pathology and Oncology Research multiple myeloma venetoclax translocation t(6;14) IGH::CCND3 personalized therapy |
| title | Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) |
| title_full | Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) |
| title_fullStr | Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) |
| title_full_unstemmed | Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) |
| title_short | Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14) |
| title_sort | effective venetoclax based treatment in relapsed refractory multiple myeloma patients with translocation t 6 14 |
| topic | multiple myeloma venetoclax translocation t(6;14) IGH::CCND3 personalized therapy |
| url | https://www.por-journal.com/articles/10.3389/pore.2023.1611375/full |
| work_keys_str_mv | AT andreacegledi effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 AT zoltancsukly effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 AT monikafekete effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 AT andraskozma effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 AT zsuzsannaszemlaky effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 AT hajnalkaandrikovics effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 AT gabormikala effectivevenetoclaxbasedtreatmentinrelapsedrefractorymultiplemyelomapatientswithtranslocationt614 |